COVID-19 vaccinations in patients with inflammatory bowel disease

Kumar, Aditi; Quraishi, Mohammed Nabil; Segal, Jonathan; Raine, Tim; Brookes, Matthew

doi:10.1016/s2468-1253(20)30295-8

Cited by 14 publications

(19 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since some vaccine technologies will be applied for the first time and the doctors do not have sufficient experience and observation with these vaccines, there is an imminent rise of several questions about the vaccination of patients with AIIRDs. Although the initial phase of COVID-19 vaccine studies was promising, it should be noted that patients with AIIRDs and/or those taking immunosuppressive drugs were excluded from these studies [12][13][14]. Recently, the Centers for Disease Control (CDC) reported that patients with an underlying autoimmune disease might be vaccinated with the mRNA vaccines but also recommended close follow-up for these subgroups of patients after vaccination [15].…”

Section: Concerns For Vaccination In Patients With Autoimmune/autoinfmentioning

confidence: 99%

A practical approach for vaccinations including COVID-19 in autoimmune/autoinflammatory rheumatic diseases: a non-systematic review

et al. 2021

View full text Add to dashboard Cite

The COVID-19 pandemic has occupied the world agenda since December 2019. With no effective treatment yet, vaccination seems to be the most effective method of prevention. Recently developed vaccines have been approved for emergency use only and are currently applied to large populations. Considering both the underlying pathogenic mechanisms of autoimmune/ autoinflammatory rheumatological diseases (AIIRDs) and the immunosuppressive drugs used in treatment, vaccination for COVID-19 deserves special attention in such patients. In this article, we aimed to give simple messages to the clinicians for COVID-19 vaccination in patients with AIIRDs based upon the current evidence regarding the use of other vaccines in this patient group. For this purpose, we conducted a "Pubmed search" using the following keywords: Influenza, Hepatitis B, Pneumococcal, and Shingles vaccines and the frequently used conventional and biologic disease-modifying antirheumatic drugs (DMARDs). Likewise, an additional search was performed for the COVID-19 immunization in patients with AIIRDs and considering such drugs. In summary, patients with AIIRDs should also be vaccinated against COVID-19, preferably when disease activity is under control and when there is no concurrent infection. Low-degree immunosuppression does not appear to decrease antibody responses to vaccines. Ideally, vaccinations should be done before the initiation of any biological DMARDs. Patients receiving rituximab should be vaccinated at least 4 weeks before or 6 months after treatment. Since tofacitinib may also reduce antibody responses, especially in combination with methotrexate, it may be appropriate to discontinue this drug before vaccination and to restart after 14 days of immunization.

show abstract

Section: Concerns For Vaccination In Patients With Autoimmune/autoinfmentioning

confidence: 99%

A practical approach for vaccinations including COVID-19 in autoimmune/autoinflammatory rheumatic diseases: a non-systematic review

et al. 2021

View full text Add to dashboard Cite

show abstract

“…(31). Of course, when different vaccines will be available, also the mechanism of action could influence the decision (32).…”

Section: Inflammatory Bowel Diseasesmentioning

confidence: 99%

How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group

et al. 2021

View full text Add to dashboard Cite

Since March 2020, the outbreak of Sars-CoV-2 pandemic has changed medical practice and daily routine around the world. Huge efforts from pharmacological industries have led to the development of COVID-19 vaccines. In particular two mRNA vaccines, namely the BNT162b2 (Pfizer-BioNTech) and the mRNA-1273 (Moderna), and a viral-vectored vaccine, i.e. ChAdOx1 nCoV-19 (AstraZeneca), have recently been approved in Europe. Clinical trials on these vaccines have been published on the general population showing a high efficacy with minor adverse events. However, specific data about the efficacy and safety of these vaccines in patients with immune-mediated inflammatory diseases (IMIDs) are still lacking. Moreover, the limited availability of these vaccines requires prioritizing some vulnerable categories of patients compared to others. In this position paper, we propose the point of view about the management of COVID-19 vaccination from Italian experts on IMIDs and the identification of high-risk groups according to the different diseases and their chronic therapy.

show abstract

“…A detailed description of its favorable risk-benefit ratio based on transparent efficacy data together with the reassurance of vaccine safety will be a crucial task to be implemented. Obviously, a vigilant surveillance on vaccine efficacy and safety, especially in the long term, is necessary, taking also into account that data in subgroups of patients with chronic diseases or during immunosuppressant therapies are still largely lacking [ 38 ]. Finally, we strongly believe that the endorsement of healthcare professionals vaccination along with the national and global healthcare organizations are essential to ensure satisfactory vaccine acceptance.…”

Section: Discussionmentioning

confidence: 99%

How to Face the Advent of SARS-CoV-2 Vaccination in IBD Patients: Another Task for Gastroenterologists

et al. 2021

View full text Add to dashboard Cite

The severity of the COVID-19 pandemic has led to an unprecedented effort to develop vaccines against SARS-CoV-2 infection since this seems to be the most effective strategy to counter the pandemic. In the past weeks, the administration of vaccines has started in different parts of the world sustaining the hype of significantly containing the impact of SARS-CoV-2 infection. However, the rapid time lapse from vaccine development to distribution has raised several concerns on its safety and efficacy. This topic is particularly felt by patients with chronic conditions and immumodulating therapies that could compromise their immune system such as inflammatory bowel disease (IBD). Here, we explore the potential future implications of the SARS-CoV-2 vaccines introduction in the IBD field, touching upon the clinical experience coming from available data on vaccinations against other infections. We also dissect the factors associated with the acceptability of SARS-CoV-2 vaccination, describing the possible strategies that gastroenterologist should adopt to reach the highest rate of vaccinations in IBD patients.

show abstract

COVID-19 vaccinations in patients with inflammatory bowel disease

Cited by 14 publications

References 8 publications

A practical approach for vaccinations including COVID-19 in autoimmune/autoinflammatory rheumatic diseases: a non-systematic review

A practical approach for vaccinations including COVID-19 in autoimmune/autoinflammatory rheumatic diseases: a non-systematic review

How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group

How to Face the Advent of SARS-CoV-2 Vaccination in IBD Patients: Another Task for Gastroenterologists

Contact Info

Product

Resources

About